Memory cells in the nose slow the influenza virus as soon as it enters the body. They reduce viral levels and may help protect against more severe illness. The study from the University of Gothenburg may help guide the development of better influenza vaccines.
Today’s influenza vaccines are given as injections in the arm and mainly stimulate immune responses in the blood. At the same time, researchers are working to develop influenza vaccines that can be administered through the nose—an effort this study helps inform. The goal is to strengthen the body’s defenses where the virus first encounters the immune system.
The researchers identified a group of memory cells, known as CD4 memory T cells, that remain in nasal tissue after an influenza infection. When the body encounters the virus again, these cells can rapidly reactivate and help other parts of the immune system fight the infection. The study shows that these cells can reduce viral replication in the nose and thereby contribute to better protection against illness.
“We show that CD4 memory T cells can remain in nasal tissue after an influenza infection and rapidly reactivate when the virus returns. This means the immune system can respond directly at the site where the virus first enters the body,” says Nimitha R. Mathew, a researcher at the Sahlgrenska Academy, University of Gothenburg, and one of the study’s lead authors.
In studies in mice, the researchers showed that these immune cells help limit viral levels and reduce tissue damage in the nose during a subsequent infection.
The researchers also analyzed cells from the nasal mucosa of healthy adults. There, they found the same type of influenza-specific memory cells, suggesting that a similar local immune defense may also exist in humans. The study is published in the Journal of Experimental Medicine.
“Many people likely already have these kinds of memory cells in their noses after previous infections, but they are not always enough to stop the virus completely. The important thing about our findings is that we now know which immune cells can limit the virus where infection begins. That knowledge can be used when developing future nasal vaccines,” says Davide Angeletti, professor at the Sahlgrenska Academy, University of Gothenburg, and also one of the study’s lead authors.
Press Contact: press@sahlgrenska.gu.se
Expert Contacts:
Nimitha R. Mathew, Researcher, Sahlgrenska Academy at the University of Gothenburg, nimitha.mathew@gu.se, +46 727291957
Davide Angeletti, Professor, Sahlgrenska Academy at the University of Gothenburg, davide.angeletti@gu.se, +46 762744894
Study: Nasal CD4⁺ tissue resident memory T cells provide cross protective immunity to influenza, https://doi.org/10.1084/jem.20251793
https://www.gu.se/en/news/immune-cells-in-the-nose-slow-influenza-virus
Nimitha R. Mathew and Davide Angeletti
Copyright: Photo: University of Gothenburg, Niclas Lunh
Merkmale dieser Pressemitteilung:
Journalisten
Ernährung / Gesundheit / Pflege, Medizin
überregional
Forschungsergebnisse, Wissenschaftliche Publikationen
Englisch

Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.
Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).
Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.
Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).
Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).